Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 4, n. 6, p. s108, 2020. DOI: 10.25251/skin.4.supp.108. Disponível em: https://skin.dermsquared.com/skin/article/view/1081. Acesso em: 22 may. 2025.